Executive Summary
Key takeaways from the latest quarterly disclosures of top-performing Chinese equity funds:
– Yongying Technology Intelligent Selection (永赢科技智选) fund, managed by Ren Jie (任桀), delivered a staggering 194.49% return in the first three quarters of 2025, with assets under management surging nearly 10 times in Q3 alone, driven by aggressive position increases in cloud computing sectors.
– The fund’s portfolio is heavily concentrated in global cloud computing, including CPO (Co-Packaged Optics) and PCB (Printed Circuit Board) segments, with major holdings like Xinyisheng (新易盛) and Zhongji Xuchuang (中际旭创).
– Great Wall Pharmaceutical Industry Selection (长城医药产业精选) fund, under Liang Furui (梁福睿), achieved a 102.02% return, emphasizing innovative drug companies and entering an ‘individual stock alpha phase’ with focused bets on clinical data and overseas licensing.
– Both funds exemplify a shift toward high-conviction, sector-specific investments in China’s evolving equity landscape, highlighting opportunities in AI-driven cloud infrastructure and biopharma innovation.
– Investors should note the scale of aggressive position increases, with some stocks seeing over 600% allocation boosts, signaling strong confidence in long-term growth narratives.
Unprecedented Gains in Chinese Equity Funds
The third quarter of 2025 has unveiled remarkable performance metrics from China’s top mutual funds, with aggressive position increases fueling returns that have captivated global investors. Yongying Technology Intelligent Selection (永赢科技智选) led the pack with a 194.49% year-to-date gain, while Great Wall Pharmaceutical Industry Selection (长城医药产业精选) joined the elite ‘double-digit return’ club. These results underscore the potency of concentrated bets in high-growth sectors like cloud computing and pharmaceuticals, reflecting broader trends in China’s capital markets. As quarterly reports flood in, the strategic moves behind these aggressive position increases offer a blueprint for navigating volatile conditions.
Fund disclosures reveal not only stellar returns but also explosive asset growth. Yongying’s assets ballooned from 1.166 billion yuan (人民币) at end-Q2 to 11.521 billion yuan (人民币) by Q3—a nearly tenfold increase. Similarly, Great Wall’s assets grew by approximately 60%, highlighting robust investor confidence. This surge aligns with China’s push toward technological self-reliance and healthcare innovation, themes that have resonated deeply with institutional players. For global fund managers and corporate executives, these aggressive position increases signal where smart money is flowing in Chinese equities.
Drivers of Outperformance
The standout funds leveraged macroeconomic tailwinds, including supportive policies from the China Securities Regulatory Commission (中国证监会) and structural shifts in global supply chains. Yongying’s focus on cloud computing tapped into soaring demand for AI infrastructure, while Great Wall’s pharmaceutical picks capitalized on regulatory approvals and overseas partnerships. Aggressive position increases in select stocks amplified gains, with portfolio managers emphasizing bottom-up stock selection over broad market bets. This approach has proven effective in a year marked by geopolitical tensions and economic recalibration, offering lessons in risk-adjusted returns.
Yongying Technology Intelligent Selection: A Cloud Computing Juggernaut
Managed by Ren Jie (任桀), Yongying Technology Intelligent Selection (永赢科技智选) has emerged as a poster child for strategic sector concentration. The fund’s Q3 report details a 91% equity allocation, with the top ten holdings exclusively dedicated to global cloud computing industries. Key segments like CPO and PCB dominate the portfolio, reflecting a conviction in the enduring growth of data-centric technologies. Stocks such as Xinyisheng (新易盛), Zhongji Xuchuang (中际旭创), and Tianfu Communication (天孚通信) each held over 1 billion yuan (人民币) in market value, underscoring the scale of these aggressive position increases.
New additions to the top holdings included Shengyi Technology (生益科技), Langqi Technology (澜起科技), and Shijia Photon (仕佳光子), with allocations ranging from 524 million to 919 million yuan (人民币). The most dramatic moves were in position boosts: Hudian Shares (沪电股份) saw a 502.17% increase, Taichenguang (太辰光) rose 642.80%, and Tianfu Communication (天孚通信) jumped 347.47%. These aggressive position changes highlight Ren Jie’s (任桀) confidence in the cloud ecosystem’s scalability. Since its inception in October 2024, the fund has delivered a cumulative return of 234%, cementing its status as a market leader.
Ren Jie’s Vision for Cloud Computing
In the Q3 commentary, Ren Jie (任桀) elaborated on the rationale behind these aggressive position increases. He noted that AI models are gaining value through pricing strategies like limited traffic and subscription shifts, with token volumes growing 100% quarter-over-quarter and computing power investments rising 10–20% quarterly. ‘Global cloud computing remains a critical focus,’ he stated, predicting that new cloud providers’ debt-fueled investments and chip-model synergies could elevate AI spending globally. By 2027, he anticipates convergence in technologies like CPO and OCS, creating fresh opportunities in light communication and PCB sectors. This outlook justifies the fund’s concentrated bets and aggressive position increases.
Great Wall Pharmaceutical Industry Selection: Innovating in Biopharma
Under the stewardship of Liang Furui (梁福睿), Great Wall Pharmaceutical Industry Selection (长城医药产业精选) achieved a 102.02% return through Q3 2025, with an 82% equity allocation focused on innovative drug companies. The top holdings included Xinda Biology (信达生物), Sansheng Pharmaceutical (三生制药), and Rejing Biology (热景生物), while new entrants like Shutaishen (舒泰神) and China Biologic Products (中国生物制药) reinforced the fund’s bias toward clinical-stage assets. Aggressive position increases were evident in stocks such as Yifang Biology-U (益方生物-U), Nuocheng Jianhua (诺诚健华), and Kanghong Pharmaceutical (康弘药业), though the fund also trimmed exposure to Yipinhong (一品红) by 7.79%.
Asset growth mirrored performance, with the fund’s size expanding from 1.132 billion yuan (人民币) to 1.790 billion yuan (人民币) in Q3—a 60% leap. Liang Furui (梁福睿) attributed this to a disciplined approach centered on three pillars: clinical data readouts, pipeline licensing abroad, and domestic sales execution. By increasing weight in non-oncology areas and prioritizing global competitiveness, the fund has entered what Liang terms an ‘individual stock alpha phase.’ This shift demands a balance between drug development certainty and overseas expansion potential, guiding the fund’s aggressive position increases in high-conviction names.
Liang Furui’s Alpha Strategy
Liang Furui (梁福睿) emphasized that innovation drug stocks are now driven by company-specific factors rather than sector-wide trends. ‘We are in an era where stock selection trumps thematic investing,’ he explained, noting that overseas licensing expectations have stabilized, allowing for more nuanced bets. His strategy involves assessing a drug’s global scarcity and commercial viability, with aggressive position increases reserved for assets with clear regulatory pathways. For instance, holdings in Xinda Biology (信达生物) and Sansheng Pharmaceutical (三生制药) reflect confidence in their R&D pipelines and international partnerships. This focus on actionable insights has enabled the fund to navigate market volatilities while delivering alpha.
Market Dynamics and Regulatory Backdrop
The aggressive position increases observed in these funds occur against a backdrop of regulatory support from bodies like the China Securities Regulatory Commission (中国证监会) and the National Administration of Financial Regulation (国家金融监督管理总局). Recent policies have encouraged capital flows into strategic sectors, including technology and healthcare, as part of China’s broader economic modernization goals. For instance, the ‘Made in China 2025’ initiative and healthcare reforms have created fertile ground for the types of investments seen in Yongying and Great Wall’s portfolios. These tailwinds are critical for investors assessing the sustainability of such aggressive position increases.
Global economic indicators also play a role. Slower growth in traditional markets has heightened interest in Chinese equities, particularly in sectors with export potential like cloud services and pharmaceuticals. Data from the People’s Bank of China (中国人民银行) shows steady capital inflows, while the Shanghai and Shenzhen stock exchanges have seen heightened activity in tech and biotech listings. The aggressive position increases by top funds signal confidence in these trends, though investors must remain vigilant about regulatory shifts, such as antitrust scrutiny or changes in healthcare pricing policies.
Implications for Institutional Investors
For fund managers and corporate executives, the disclosures offer actionable intelligence. The aggressive position increases in cloud computing suggest that AI and data infrastructure remain long-term plays, while pharma bets highlight the value of clinical milestones. Diversification within these sectors is key, as evidenced by Yongying’s focus on sub-segments like CPO and Great Wall’s emphasis on licensing deals. Investors should monitor quarterly reports for similar aggressive position increases, as they often precede broader market movements. Additionally, leveraging resources like the Shanghai Stock Exchange (上海证券交易所) disclosures can provide early signals on sector rotations.
Strategic Insights for Portfolio Allocation
The success of Yongying and Great Wall underscores the importance of sector-specific expertise and timely position adjustments. Aggressive position increases in high-conviction stocks can amplify returns, but they require deep due diligence on technological trends and regulatory landscapes. For instance, Yongying’s bets on cloud computing align with global AI adoption curves, while Great Wall’s pharma holdings benefit from China’s growing role in biopharma innovation. Investors should consider emulating this approach by allocating to funds or stocks with clear growth narratives and transparent disclosure practices.
Risk management remains paramount. The concentrated nature of these aggressive position increases exposes portfolios to sector-specific shocks, such as technological disruptions or clinical trial failures. Diversifying across sub-sectors and maintaining liquidity buffers can mitigate these risks. Moreover, staying abreast of policy announcements from the China Securities Regulatory Commission (中国证监会) and other bodies is essential for anticipating market shifts. The aggressive position increases seen in Q3 may not be replicable in all environments, so flexibility is crucial.
Case Study: Cloud Computing Value Chain
Yongying’s portfolio illustrates how aggressive position increases can capitalize on entire value chains. From component suppliers like Hudian Shares (沪电股份) to integrators like Zhongji Xuchuang (中际旭创), the fund’s bets span multiple layers of the cloud ecosystem. This holistic approach leverages synergies across computing, communication, and storage, as highlighted by Ren Jie (任桀). Investors can apply this model by mapping out dependency networks within high-growth sectors, identifying companies with scalable technologies and strong IP positions. The aggressive position increases in CPO and PCB stocks, for example, reflect anticipation of 2027 technology inflections.
Forward-Looking Market Guidance
The Q3 disclosures from Yongying and Great Wall provide a roadmap for navigating Chinese equities in the coming quarters. Aggressive position increases in cloud computing and pharma are likely to persist, driven by AI commercialization and healthcare innovation. Investors should prioritize funds with proven stock-picking acumen and transparent strategy communications. Monitoring manager commentaries, such as those from Ren Jie (任桀) and Liang Furui (梁福睿), can yield early insights into emerging trends. Additionally, leveraging tools like the Shenzhen Stock Exchange (深圳证券交易所) data feeds can enhance decision-making precision.
In the short term, expect volatility as markets digest earnings seasons and policy updates. However, the structural drivers behind these aggressive position increases—such as digital transformation and aging demographics—support long-term optimism. Investors are advised to review their allocations quarterly, emphasizing sectors with regulatory tailwinds and global relevance. By adopting a disciplined, research-driven approach, similar to that of top-performing funds, stakeholders can capitalize on China’s equity growth story while managing risks effectively.
Call to Action for Global Stakeholders
Engage with Chinese equity markets by studying quarterly fund reports and regulatory filings. Consider allocating to actively managed funds that demonstrate aggressive position increases in high-growth areas, or replicate their strategies through direct stock investments. Resources like the China Fund News (中国基金报) offer timely updates, while international platforms provide cross-border context. For hands-on guidance, consult with financial advisors specializing in Asian markets, and attend industry conferences featuring insights from managers like Ren Jie (任桀) and Liang Furui (梁福睿). The window for leveraging these aggressive position increases is open—act now to align your portfolio with China’s next wave of innovation.